Abstract: Millions of deaths worldwide are caused by the aetiological agent of tuberculosis, Mycobacterium tuberculosis. The increasing prevalence of this disease, the emergence of drug-resistant strains, and the devastating effect of human immunodeficiency virus coinfection have led to an urgent need for the development of new and more efficient antimycobacterial drugs. The modern approach to the development of new chemical compounds against complex diseases, especially the neglected endemic ones, such as tuberculosis, is based on the use of defined molecular targets. Among the advantages, this approach allows (i) the search and identification of lead compounds with defined molecular mechanisms against a defined target (e.g. enzymes from defined pathways), (ii) the analysis of a great number of compounds with a favorable cost/benefit ratio, and (iii) the development of compounds with selective toxicity. The present review describes the enzymes of the purine salvage pathway in M. tuberculosis as attractive targets for the development of new antimycobacterial agents. Enzyme kinetics and structural data have been included to provide a thorough knowledge on which to base the search for compounds with biological activity. We have focused on the mycobacterial homologues of this pathway as potential targets for the development new antitubercular agents.
INTRODUCTION
Infectious diseases stand as a global concern along centuries of human history, claiming for millions of lives every year. Tuberculosis (TB) pictures as a main player among these, since approximately one third of the world's population is infected with Mycobacterium tuberculosis (MTB), the aetiological agent of human TB [1], which is responsible for more human deaths than any other single infectious agent. Approximately 95% of TB cases occur in developing nations, which account for 98% of the deaths worldwide [2, 3] . These statistics are inevitable, as a reflection of financial constraints of countries where very few resources are available to ensure proper treatment and where human immunodeficiency virus (HIV) infection is common, which wanes immunity, thereby reactivating the contained, but not eradicated, mycobacterial infection, both forging a deadly synergy [4, 5] . The demographical concentration of TB deaths among developing nations and higher mortality rates among ages ranging from 25 to 54 years, the most economically fruitful years of life, causes substantial losses in productivity and contributes to the impoverishment of third-world countries [6] . Several countries have been reaching treatment success's substantially below average due, in part, to the complications caused by the HIV/AIDS epidemic and the widespread emergence and dissemination of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains [7, 8] .
Among the existing therapeutic agents, isoniazid and rifampicin stand as the most effective first-line antimycobacterial drugs [9] prescribed. However, drug-resistant TB is more difficult and expensive to treat, and more likely to be fatal, thus leading to the use of second-line drugs, which are less effective and more toxic [10, 11] . The emergence of MDR/XDR-TB strains has become a worldwide concern, leading to a requirement for the development of new antimicrobial agents, which, in turn, demands the identification of suitable drug targets. The modern approach to the development of new chemical compounds against complex diseases, especially the neglected endemic ones, such as TB, is based on the use of defined molecular targets. Among the advantages, this approach allows (i) the search and identification of lead compounds with defined mo-There is an urgent need for the development of new and more efficient antimycobacterial agents. However, little interest has been shown by the pharmaceutical industry, which has not been necessarily attributed to the high investment needed to develop a new anti-TB compound, but to the small financial return awaited, since most TB cases occur in developing countries [2] .
THE PURINE SALVAGE PATHWAY
In most organisms, nucleic acids undergo active turnover through catabolic processes to form free purine bases [12] . Purine nucleotides may be derived from preformed purine bases and nucleosides by the so-called salvage pathways, or they may be formed de novo from simpler precursors. The ribose 5'-phosphate moiety is derived from 5'-phospho--D-ribose 1'-diphosphate (PRPP), which takes part in both de novo and salvage pathways of purine and pyrimidine nucleotides, and acts as a common regulator [13] .
In the purine salvage pathway, adenine, guanine and hypoxanthine nucleobases are reconverted to their corresponding nucleotides (AMP, GMP and IMP, respectively). In contrast, the de novo pathway leads to the formation of inosine 5'-monophosphate (IMP), which then diverges into separate sets of anabolic reactions that synthesize adenosine 5'-monophosphate (AMP) and guanosine 5'-monophosphate (GMP) [14] .
Purine metabolism is conserved among eukaryote and prokaryote organisms, including MTB. Although de novo and salvage pathways have not been extensively detailed in MTB, it is known that the bacillus expresses enzymes of both pathways [15] , thereby not being a purine auxotroph like other obligatory intracellular parasites such as Toxoplasma gondii [13] , Plasmodium falciparum [16] and Leishmania donovani [13] . Whether MTB will sway between de novo or salvage pathways is still an unclear question. Since mycobacteria is able to suffice its metabolic needs for nucleotides from simpler substrates, a high energy demanding process, while is also capable of scavenging free nitrogenous bases from the medium, over passing up to 11 chemical steps, it seems that under conditions of low energy availability or rapid multiplication, the salvage pathway should be the main source of maintaining the nucleotide pool.
MTB adapts its own metabolism under distinct stages of TB infection, in response to microenvironments such as necrotic or caseous regions that are remote from the cavity surface of host lungs, where the availability of oxygen, nutrients and drugs is likely to be restricted. The metabolism required for sustaining mycobacterial survival during TB persistence and latency is still poorly understood. Transcriptional profiling has shown that a ribonucleotide reductase (RR; EC 1.17.4.1) encoded by nrdZ is up-regulated on latent bacillus, which indicates that a pool of deoxyribonucleotides is required either for maintenance of chromosomal integrity or for the process of DNA repair and replication that is expected to occur during TB reactivation [17] .
The purine salvage pathway in MTB is a yet little explored possibility for drug development, and chemical agents with novel mechanisms of action are needed to combat emerging MDR/XDR-TB strains. The selective activity of 2-methyladenosine (methylAdo; an adenosine analogue) against MTB has provided proof of concept for the use of nucleoside analogs as antimycobacterial agents [18] . A thorough understanding of the enzymes involved in purine salvage and metabolism could lead to identification of nucleoside analogs that potently and selectively inhibit MTB viability [19] .
Although data on purine metabolism is relatively scarce in MTB, it is believed that the purine salvage pathway is used when the bacillus uptakes hypoxanthine, guanine, and adenine from the external medium, which are subsequently converted to, respectively, IMP, GMP, and AMP [20] . Several homologues to enzymes of the purine salvage pathway have been identified in the genome sequence of MTB H37Rv [21] . Purine bases, nucleosides, and nucleotides can be interconverted through the activities of adenosine deaminase (EC 3.5.4.4, add, Rv3313c), adenosine kinase (EC 2.7.1.20, adoK, Rv2202c), 5'-nucleotidase (EC 3.1.3.5, Rv2232), hypoxanthine-guanine phosphoribosyltransferase (EC 2.4.2.8, htp, Rv3624c), adenine phosphoribosyltransferase (EC 2.4.2.7, apt, Rv2584c), purine nucleoside phosphorylase (EC 2.4.2.1, deoD, Rv3307), purine nucleosidase (EC 3.2.2.1, iunH, Rv3393), inosine monophosphate dehydrogenase (EC 1.1.1.205, guaB2, Rv3411c), adenylosuccinate synthase (EC 6.3.4.4, purA, Rv0357c), adenylosuccinate lyase (EC 4.3.2.2, purB, Rv0777), guanylate kinase (EC 2.7.4.8, gmk, Rv1389), adenylate kinase (EC 2.7.4.3, adk, Rv0733), and guanosine monophosphate synthase (EC 6.3.5.2, guaA, Rv3396c) (Fig. 1) .
Singular features of this pathogen such as enzymes either of essential metabolic pathways exclusive to the microorganism [22] or of purine and pyrimidine [23] salvage pathways with unique characteristics as compared to the human host, can be explored to direct efforts towards selective target drug development. Although intermediates of the purine salvage pathway seem to be alike for both prokaryotic and eukaryotic organisms, differences can occasionally be found in the primary structure and properties of homologous enzymes. Nucleotide metabolic pathways are a good source of new targets for antibacterial drugs, as the enzymes/pathways involved are often different from their human counterparts. The purine salvage pathway is one of the promising pathways for the development of novel nucleoside analogs with anti-TB activity [13] .
Nucleoside analogs are prodrugs resembling natural nucleosides that usually must be metabolized intracellularly to active compounds. They are thus an important class of drugs used in the treatment of viral infections and cancer that may prove to be particularly useful in treating drug-resistant TB, since their mechanism of action is likely to be different from those of existing therapies [18] . These antimetabolites comprise a class of drugs that inhibit DNA synthesis either directly or through inhibition of DNA precursor synthesis of de novo or salvage pathways [24] .
A better understanding of the characteristics of the enzymes involved in purine salvage in MTB should aid in the rational design of purine analogs that can selectively inhibit MTB replication and survival. Ideally, this class of compounds should be active against strains of MTB that are resistant to the agents currently used to treat this disease and may, hopefully, also target latent disease.
Here we describe the enzymes of the purine salvage pathway that have been identified in the MTB genome (Fig. 1) , their main characteristics, the state-of-art of ongoing researches on each enzyme, the resemblance to their human counterparts, and a brief discussion of features that might be explored for identification or development of specific inhibitors. Encoded by the add gene (MTB Rv3313c, 1098 bp, 366 aa, 39743.10 Da, and Isoelectric point (pI) = 5.36), adenosine deaminase (ADD) plays an important role in the purine salvage pathway, catalyzing the irreversible hydrolytic deamination of (deoxy)adenosine to generate (deoxy)inosine (Fig. 2) . There are nearly one hundred compounds capable of binding to ADD, being some substrates and most inhibitors that display different types of inhibition [25] [26] [27] . This enzyme belongs to the superfamily of metallodependent hydrolases (also called amidohydrolase superfamily), a large group of proteins (which includes AMP and adenine deaminases, among others) that show conservation in their threedimensional fold and in details of their active sites. The vast majority of the members have a conserved metal binding site (zinc metalloenzyme), involving three histidines and one aspartic acid residue. In the common reaction mechanism, the metal ion (or ions) deprotonates a water molecule for a nucleophilic attack on the substrate [12, 28, 29] .
PURINE SALVAGE ENZYMES
Enzyme activity for the human homologue has been observed in all human tissues, owing to at least three isoforms [30] . In humans, rare genetic defects have been described for this gene and associated to specific diseases. Deficiency in this enzyme causes a form of severe combined immunodeficiency disease (SCID), where there is a dysfunction of both B and T lymphocytes with impaired cellular immunity and decreased production of immunoglobulins. This condition is invariably fatal at an early age due to overwhelming infection. In case an appropriate donor is available, SCID patients can be treated with bone marrow transplantation. Gene therapy, in combination with replacement enzyme infusion has been employed as an alternative attempt to treat this disorder [12, 14] . The enzyme's coding DNA sequence is conserved in cells of chimpanzee, dog, cow, mouse, rat, chicken, zebrafish, Caenorhabditis elegans, Schizosaccharomyces pombe, Saccharomyces cerevisiae, Kluyveromyces lactis, and P. falciparum. The prokaryotic homologue has also been extensively studied. The synthesis of the E. coli enzyme, which is inhibited by conformycin (K i = 30 nM), is induced by adenine and hypoxanthine [31] . In Salmonella typhimurium, however, it is apparently synthesized constitutively, and in low amounts [32] .
A number of studies have been reported for ADD from various sources, including X-ray crystallography for the complex with 6-hydroxyl-1,6-dihydropurine ribonucleoside, a nearly ideal transition-state analogue [28] . However, there has been no publication regarding MTB ADD (MtADD). Our group has PCR-amplified and pET23a(+)-cloned the MTB add gene. The mycobacterial recombinant enzyme was expressed in its insoluble form in all electrocompetent E. coli commercial variants available for heterologous expression tested to date. Although homogeneous MtADD could be obtained through a sequence of anion exchange, gel filtration, and hydrophobic interaction chromatographic steps, protein solubiliza-tion processes resulted in protein with no activity so far. Soluble and active MtADD protein expression is underway (unpublished data). Encoded by the adoK (previously named cbhK) gene (MTB Rv2202c, 975 bp, 325 aa, 34439.90 Da, and pI = 4.51), adenosine kinase (AK) catalyses the phosphorylation of adenosine to AMP (Fig. 3) , an important step in the purine salvage pathway, using adenosine 5'-triphosphate (ATP) as a phosphate donor, and releasing adenosine 5'-diphosphate (ADP). Enzyme activity of most AKs is dependent on Mg
2+
. In agreement with previous observations with the human homologue [33] [34] [35] , deoxyadenosine is a poor substrate for MTB AK (MtAK) [36] . AK belongs to the phosphofructokinase B family of carbohydrate and nucleoside kinases, a family of structurally related enzymes which includes ribokinase and fructokinase, among others [37] . AK is found in most eukaryotes, fungi, plants, and parasites, but it is seldom found in bacteria [36] . MtAK shows greater homology to ribokinases than to other AKs. Not surprisingly, it was previously classified as a hypothetical sugar kinase. AK activity has been biochemically proven in MTB [18] , being the first bacterial homologue to be characterized.
In 1994, the Tuberculosis Antimicrobial Acquisition and Coordinating Facility was established by the National Institute of Allergy and Infectious Diseases, as an attempt to support research and design new drugs to combat TB [38] . Many purine analogues with selective activity against MTB were identified. Methyl-Ado was one of the compounds whose MtAK-phosphorylation yielded an active form with highest index of potency and selectivity [39] , being active against MTB drug-resistant strains and against mycobacteria incubated under latency simulating conditions. It is important to note that the high selectivity for MTB attributed to this com- pound is due to its extremely low cytotoxic level to human cells. In humans, clinically useful antimetabolites, such as base or nucleoside analogues, are metabolized to biologically active nucleotides. The primary target of methyl-Ado appears to be an enzyme involved in protein synthesis. Although the enzyme responsible for this activity has not yet been identified, it is known that the primary enzyme involved in the activation of methyl-Ado in MTB is AK.
The mycobacterial homologue exhibits several physicochemical and three-dimensional features considerably different as compared to AKs from other sources [19] . The differences between human and mycobacterial enzyme homologues justify selective activation of methyl-Ado by the latter. Differently to AKs from various sources, and similarly to other ribokinases, MtAK catalytic activity is stimulated in the presence of monovalent metal ions (ionic requirement) such as K + [40, 41] . Formerly thought to be a tetramer, MtAK's native form is actually a dimer formed by an extendedsheet [42, 43] , somewhat different from the monomeric form of human AK [44] [45] [46] . High resolution structures for MtAK have been determined (PDB accession codes 2PKM, 2PKF, 2PKK, and 2PKN), and demonstrate that the active site of the enzyme is in an open conformation in absence of ligands (apo form), and upon adenosine binding a LID domain undergoes a large conformational change to close the active site of this protein. In the closed conformation, the LID forms direct interactions with the substrate and residues of the active site [42] . The human and mycobacterial enzymes also share differences with respect to their respective preferences for phosphate donors [18, 47] , as the mycobacterial enzyme activity was shown to be higher with guanosine 5'-triphosphate (GTP) and deoxy(d)GTP than with ATP. Furthermore, the considerably higher rate of methyl-Ado phosphorylation by MtAK is also responsible for the selective activity of this compound against mycobacteria [19] . Although it has recently been questioned whether MtAK functions as an adenosine kinase in M. tuberculosis cellular setting [48] , the biological role of MtAK still awaits further experimental evidence such as gene replacement studies. At any rate, methyl-Ado selective activity against MtAK has provided proof of concept for the use of nucleoside analogues as antimycobacterial agents [36] . From a drug development point of view, the fact that MtAK differs in substrate, inhibitor, and phosphate donor specificities from the human homologue is of particular importance, because these results indicate that mycobacterial and human enzymes are different enough to allow selective activation of adenosine analogs, such as methyl-Ado. AK is not required for the in vitro growth of MTB, which would suggest that inhibitors of this enzyme are not candidates for drug development. However, it is possible that this enzyme does have a critical role in the growth of MTB in a human cell. If this turns out to be the case, then these inhibitors may also be considered as leads for further drug development. Moreover, it has been suggested that MtAK may be utilized for selective phosphorylation of nucleoside analogs to metabolites active against MTB [36] . 5'-nucleotidases (5'-NT) are a family of enzymes that catalyze the hydrolytic dephosphorylation of (deoxy)ribonucleoside monophosphates to the corresponding nucleosides (Fig. 4) and regulate cellular nucleotide and nucleoside levels. Since cellular nucleotides are derived either from de novo synthesis or salvage pathways, this enzyme is critically positioned at the interface of both processes and may determine the fate of extra and intracellular nucleotides.
Unlike the well studied AK, many of the catabolic nucleotidases have only recently been cloned and characterized. 5'-NTs and nucleoside kinases catalyze reverse reactions, forming substrate cycles in which phosphorylation and dephosphorylation of nucleosides create a dynamic balance between pathways to rapidly respond to changes in metabolic conditions by increasing or decreasing the concentration of a particular nucleotide. Thereby, aside from maintaining (deoxy)ribonucleotide pools, substrate cycles that are formed with the kinase and nucleotidase activities are also likely to regulate the activation of nucleoside analogues [49] . A few studies have suggested that since 5'-NTs can dephosphorylate the monophosphate forms of many nucleoside analogues that are administered in cancer and viral infection treatments, increased levels of nucleotidase activity can inhibit their activation, possibly playing a role in resistance to these compounds [24] . The expression of this enzyme has been observed in bacteria, plant and vertebrate cells. However, it is not clear whether it is indeed present in MTB (Mt5'-NT; MTB Rv2232, 876 bp, 291 aa, 30662.20 Da, and pI = 7.14). Although there are significant differences with respect to the range of substrate hydrolyzed and substrate specificity, 5'- mononucleotides appear to be the most commonly hydrolyzed. Its physiological function is possibly disparate among various organisms and tissues, and probably extends beyond its catalytic activity. Notwithstanding their source, 5'-NTs are usually present as two main biochemical forms: membrane-bound and soluble [24, 50] . Polyphenolic substances that display antitumor activity (with no general cytotoxic effects observed) and inhibit 5'-NT activity from different sources have been isolated from plants [51] [52] [53] .
Our group has PCR-amplified and pET23a(+)-cloned the MTB Rv2232 gene, that has been assigned in silico to encode a 5'-NT enzyme in MTB. The identity of the cloned sequence was confirmed by automated nucleotide sequencing and the recombinant encoded protein was expressed in its soluble form in electrocompetent E. coli BL21(DE3) host cells. Availability of homogeneous Mt5'-NT will allow measurements of enzyme-catalyzed chemical reactions to provide experimental evidence whether or not the Rv2232 DNA sequence codes for a mycobacterial 5'-NT activity (unpublished data).
Phosphoribosyltransferase Family Enzymes
The family of phosphoribosyltransferase (PRTase) enzymes show a common catalytic reaction of pyrophosphate (PP i ) displacement from PRPP by a nitrogen-containing nucleophile, such as ammonia, adenine, guanine, hypoxanthine, xanthine, orotate or uracil, producing a -substituted ribose 5-phosphate and PP i [54, 55] . These enzymes take part in key steps of purine, pyrimidine, and pyridine (nicotinamide) nucleotide synthesis or salvage, as well as in aromatic amino acids (histidine and tryptophan) biosynthesis, being present in eukaryotic and prokaryotic organisms [56] .
Although PRTase proteins show remarkable tertiary and quaternary structure conservation [57, 58] , a PRPP conserved binding motif of 12 amino acids (MLVDDVITAGTA), shared with PRPP synthetases, is only observed among PRTase family members involved in nucleotide synthesis or salvage pathways [55] , being the main primary structure unifying characteristic for this group of enzymes, typifying the 'type I PRTases'.
Crystallographic structures of type I PRTases have revealed a conserved nucleotide binding Rossmann fold, where a common CORE of five parallel -sheets are surrounded by -helices at one side, and an / motif at the other [55] [56] [57] . At the C-terminal portion of this / motif, an 11-amino-acid long conserved flexible loop (RKEAKDHGEGG) is involved in binding and partial solvent occlusion of the nitrogenous base substrate [57, 58] . The readers may refer to a mini-review by Sinha and Smith for a more in-depth discussion on the three-dimensional structures of type I PRTases [55] .
Other shared features of type I PRTases are: catalytic role of conserved lysine residues [54] , sequential kinetic mechanismseither random or ordered [57] , homodimeric assembly of their tertiary structures [55] , loop closure upon substrate binding on adjacent subunit binding site [56, [58] [59] [60] , and absolute requirement for magnesium divalent ion for catalysis, where Mg 2+ -PRPP has already being proved to be the true substrate for some PRTases [61] .
In purine nucleotide metabolism, PRTase enzymes are involved in the first step of de novo synthesis (glutamine phosphoribosylpyrophosphate amidotransferase, E.C. 2.4.2.14) [62] ; and two other enzymes are responsible for nucleobases salvage pathway, hypoxanthine-guanine phosphoribosyltransferase and adenine phosphoribosyltransferase, which catalyze nucleotide formation in a single catalytic step from the corresponding free nitrogenous bases available from catabolism. The pivotal role that these enzymes play in the purine salvage pathway denote their potential as chemotherapeutic targets for parasitic diseases, since all four purine nucleobases (xanthine, hypoxanthine, guanine, and adenine) are incorporated into the nucleotide pool via the PRTase reactions [13] , and their characterization might reveal insightful data on metabolic balance between host and parasites [20] . -dependent reversible transfer of the 5'-phosphoribosyl moiety from PRPP to the N9 position of 6-oxopurines (guanine, hypoxanthine, and xanthine) to form the corresponding ribonucleotides, GMP, IMP, and xanthosine 5'-monophosphate (XMP), and PP i [20] (Fig. 5 ). We have previously described PCR amplification, cloning, DNA sequencing, heterologous protein expression in electrocompetent E. coli BL21(DE3) host cells, purification to homogeneity, and biochemical characterization of a predicted MTB HGPRT (MtHGPRT) [20] . Correct assignment to the structural gene encoding MtHGPRT was probed by measurement of the biological activity of the recombinant enzyme by steady-state kinetics. Apparent steady-state kinetic constants and substrate specificities for homogeneous MtHGPRT were determined for hypoxanthine, guanine, xanthine, and PRPP ( Table 1) . The recombinant enzyme-catalyzed chemical reaction obeys Michaelis-Menten kinetics for all substrates tested; however, no activity with xanthine as substrate could be detected, indicating that the recombinant MtHGPRT protein does not utilize xanthine. The k cat /K M ratios indicate that MtHGPRT has a slightly higher preference for hypoxanthine (18 ± 7 x 10 3 M -1 s -1 ) than for guanine (5.6 ± 1.5 x 10 3 M -1 s -1 ) as co-substrate [20] .
Transition-state analogues, known as immucillin 5'-phosphates, were shown to be tight-binding inhibitors of HGPRT enzyme activity. Crystallographic structures and structural analyses of these inhibitors in complex with human HGPRT (PDB accession code 1BZY) [63] and with the P. falciparum homologue (PDB accession code 1CJB) [64] have shown an almost identical binding mode, which suggests that it may be difficult to design specific parasite HGPRT inhibitors [65, 66] , even though chlorine substituted at 6-position, and nitrogen substituted at 8-position (6-chloroguanine, 8-azaguanine, and 8-azahypoxanthine) exhibited high selectivity towards parasite HGPRT [66] . More recently, acyclic nucleoside phosphonates, 2-(phosphoalkoxy)alkyl derivates of purine and pyrimidine bases, have been shown to be potent and highly selective inhibitors of malarial HGPRT, with K i values in the M range [65] .
Human HGPRT, encoded by the hgprt1 gene and located at chromosome Xq26.1, presented 218 amino acids and a molecular mass of 24448 Da (GenBank accession number: NP_000185.1). As for MtHGPRT, the human homologue also shows no activity with xanthine as co-substrate [67] . This characteristic lack of xanthine metabolism in humans and its presence in some parasites can be exploited to develop antiparasitic drugs, since xanthine analogues may selectively inhibit the parasitic PRTase, not interfering with host purine salvage pathway [13] . However, specific inhibitor development for MtHGPRT should exploit features other than xanthine usage, as low sequence identity (24.9%, assigned by pairwised amino acids sequence alignment [68] ) may indicate non conservation of key catalytic residues, distinct steady-state kinetic constants and mechanism. Human HGPRT follows a sequential ordered mechanism: Mg 2+ -PRPP binds first followed by 6-oxopurine base binding. After the phosphoribosyl transfer, PP i dissociates from the complex and the nucleoside monophosphate is released in the ratelimiting step [69] . Although MtHGPRT true steady-state kinetic constants and the enzyme kinetic mechanism have not been shown yet, these efforts are currently underway in our research group. These results should provide experimental data on which to base the rational design of MtHGPRT inhibitors.
Adenine Phosphoribosyltransferase (EC 2.4.2.7)
(other designations: APRT, AMP diphosphorylase, AMP pyrophosphorylase, and transphosphoribosidase)
Encoded by the apt gene (MTB Rv2584c, 672 bp, 223 aa, 23155.60 Da, and pI = 10.13), adenine phosphoribosyltransferase (APRT) is specific for 6-aminopurine nucleobases, catalyzing the Mg 2+ -dependent reversible transfer of the 5'-phosphoribosyl moiety from PRPP to adenine, resulting in the formation of AMP and PP i [70] (Fig. 6) . Several parasites deficient in APRT activity employ adenine deaminase (EC 3.5.4.2) to deaminate adenine to hypoxantine, which is substrate for HGPRT. On the other hand, parasites that do have APRT activity usually lack adenine deaminase activity [13] , as observed for MTB.
Compared to other purine and pyrimidine PRTases, studies of APRT are so far scarce. The crystallographic structures available on public databases indicate APRT as a well characterized member of type I PRTases, but presenting a unique purine binding pocket that slightly opens to accommodate the larger AMP ligand [70, 71] . APRT crystallographic data (PDB accession codes 1L1Q, 1L1R, 1G2P and 1G2Q) suggest that loop closure upon substrate binding occurs in the same subunit, and not over the adjacent subunit, distinguishing such enzymes amongst the type I PRTases [72, 73] . Since structural analyses of orotate phosphoribosyltransferase (OPRT; EC 2.4.2.10) and APRT show a single metal binding site [74] whereas HGPRT crystallographic data suggest a second Mg 2+ binding site [59, [63] [64] [65] , APRT is considered more similar to OPRT homologues, a type I PRTase that catalyzes the fifth step of de novo synthesis of pyrimidine nucleotides, than to other purine PRTases. APRT enzymes can be further subdivided into short-and longAPRTs based on their amino acid sequences. Short-APRT enzymes present primary structure of 120 to 180 amino acids and include human, yeast, E. coli, and Giardia genus APRTs [72] . Long-APRT enzymes have a C-terminal extension of 50 amino acids, which is comprised of approximately 230 amino acids, and is found in all Leishmania genus and Trypanossoma brucei homologues [72] . The enzyme from the MTB H37Rv laboratorial strain belongs to the long-APRT group, while the ones from most of the remaining MTB strains are classified as short-APRTs. This C-terminal extension, initially attributed only to Leishmania, expands the dimer interface by wrapping around the adjacent subunit and double the total buried solvent-accessible surface area upon dimer formation [71] .
Human APRT, encoded by the aprt gene and located at chromosome 16q24, has two isoforms, one with 134 amino acids and other with 180 amino acids (GenBank accession number NP_001025189.1 and NP_000476.1), as a result of distinct splicing processes. Its crystallographic structure (PDB accession code 1ORE) analysis led to the proposal of two conserved amino acids in the active sites of APRTs that are involved in 6-aminopurine recognition over different purines: Leu/Ile159 and Ala131 (numbered according to 1ORE structure) [74] . MTB APRT (MtAPRT) presents 29% and 42% identity to human short and long APRT isoforms, respectively, when the 50 amino acid C-terminal extension is disregarded; and both Leu159 and Ala131 are conserved within its primary sequence. Further attempts to fully characterize MtAPRT should be accomplished to highlight which mycobaterial features might be exploited for inhibitor development to ensure that no significant interactions are made with the human APRT isoforms. Amongst PRTase enzymes that bind 6-oxopurines, positions 159 and 131 are occupied by a lysine and an aspartic acid, respectively. Both these charged amino acids are believed to direct hydrogen bond to the nitrogenous base, defining enzymes' specificity [74] . However, double knockout experiments of HGPRT and xanthine phosphoribosyltransferase (EC 2.4.2.22) enzymes in L. donovani parasites have shown that besides presenting dramatically diminished infecting capability, such parasites still persisted in culture when no purine source other than hypoxanthine was supplemented. These data reveal that, under conditions of high expression and in the absence of other PRTases, APRT is able to use this 6-oxopurine base as substrate to further synthesize purine nucleotides, since Leishmania genus rely solely on salvage pathways for purine and pyrimidine synthesis [75] . Taken together, these results imply that mechanisms other than conserved amino acid residues at positions 131 and 159 are related to 6-amino and 6-oxopurine recognition, and further investigations are necessary to fully describe and distin- Encoded by the deoD (alternatively named punA) gene (MTB Rv3307, 807 bp, 268 aa, 27539.4 Da, and pI = 5.75), purine nucleoside phosphorylase (PNP) is primarily assigned as a purine nucleoside salvage enzyme, although it is also involved in pyrimidine and pyridine metabolism [76] . It catalyzes the reversible phosphorolysis of the N-glycosidic bond of -purine (deoxy)ribonucleosides to generate -(deoxy)ribose 1-phosphate and the corresponding purine bases [77, 78] (Fig. 7) . Structurally, PNP enzymes are subdivided according to their quaternary structures into homotrimeric and homohexameric, which implies distinct substrate specificities. Homotrimeric PNPs are highly specific for 6-oxopurines, their nucleosides (inosine, deoxyinosine, guanosine, and deoxyguanosine), and some analogues, whereas homohexameric PNPs additionally accept 6-aminopurine (adenine), their nucleosides and many analogues as substrates [79] . Among homotrimeric PNPs, the rates of phosphorolysis and/or synthesis of adenosine, when detectable, are negligible or extremely low [80, 81] . Readers are suggested to refer to reference [79] for an authoritative review on PNP structural properties.
MTB PNP (MtPNP) has been shown to be trimeric [82] , like mammalian PNP, which distinguishes the mycobacterial homologue from the hexameric prokaryotic enzymes [83, 84] . MtPNP has been numbered among the top 100% persistence targets by the TB Structural Genomics Consortium (www.webtb.org). However, the physiological role of PNP in MTB remains to be demonstrated. We have reported cloning, expression, purification, and studies on slow-onset inhibition by a transition-state analogue, immucillin-H (ImmH), including a detailed analysis of ImmH component parts (dissection by parts) and their effects on MtPNP enzyme activity [82] . We have also determined MtPNP structure in complex with ImmH (PDB accession codes 1G2O and 1I80) [85] , indicating that mimicry of transition-state features is the dominant force for ImmH tight binding [86] . On evaluation of size and charge distribution effects in transition-state analogues that inhibit MtPNP, it has been demonstrated that over-the-barrier transition-state analogues (DADMe-Immucillin compounds) have increased affinity for mycobacterial enzyme, which resulted from more favorable ion-pair formation between the cationic mimic of the oxocarbenium ion and the anionic phosphate nucleophile [87] . More recently, we have solved the X-ray crystallographic structure of MtPNP in complex with inorganic phosphate and discussed structural changes resulting from ImmH binding [88] .
The human PNP (HsPNP) counterpart is encoded by the np gene, also assigned as pnp1, located at chromosome 14q13.1, which codifies a 289 amino acid transcript (GenBank accession number NC_000014.8). HsPNP is also classified as a homotrimeric PNP. Pairwise amino acid sequence alignment of the mycobaterial and human homologues indicates a 34.81% identity and 18.43% strong similarity between them. Besides their similarity, it should be pointed out that the design of inhibitors with higher affinity for MtPNP than for HsPNP is a feasible goal since it has been shown that they appear to have slightly different transition states [87] and structural features [89] [90] [91] that may be exploited to achieve specificity [85, [92] [93] [94] [95] [96] [97] [98] [99] [100] . In addition, it has recently been shown that even though bovine and HsPNP homologues share 87% sequence identity and have full conservation of active site residues, inhibitors with differential specificity can still be designed [101] .
Although MtPNP has been clearly classified among the homotrimeric enzymes, there was no experimental data probing MtPNP specificity for adenosine. MtPNP substrate specificity was determined by measurements of initial velocity employing different substrates, including 6-aminopurine, as well as determination of true steady-state kinetic parameters, product inhibition, substrates and products binding studies (spectrofluorimetry and surface plasmon resonance), pH-rate profiles, temperature effects, and solvent kinetic isotope effects to provide enzyme kinetic and chemical mechanisms [102] . MtPNP was more specific to guanosine N7 methyl analogues, 2-amino-6-mercapto-7-methylpurine ribonucleoside (MESG) and 7-methylguanosine [103] , than any natural nucleoside tested, which is largely due to increased catalytic constant values, since K M values were of similar magnitude [102] . HsPNP has been shown to be more specific for natural substrates, such as Fig. (7) . Purine nucleoside phosphorylase catalyzes the reversible phosphorolysis of purine (deoxy)ribonucleosides to generate -(deoxy)ribose 1-phosphate and the corresponding purine bases.
inosine and guanosine, than to MESG [100] . In addition, the HsPNP K M value for MESG (358 μM; [100] ) is approximately 12-fold larger than that for MtPNP [102] . These differences imply that enzyme inhibitors more specific for MtPNP may be designed based on the chemical functional group substitutions of MESG, in particular the sulfur at the sixth position of the purine base. Our results also indicate that the rate of phosphorolysis of adenosine by MtPNP is undetectable or, at the most, negligible [102] ; in agreement with homotrimeric PNP enzymes that are not able to catalyze the phosphorolysis of 6-aminopurine nucleosides to an appreciable extent. A comparison between the three-dimensional structures of ternary complexes of MtPNP and bovine spleen PNP in complex with a transition-state analogue (ImmH) and inorganic phosphate showed that the contacts in their catalytic sites are similar, but not identical [85] . Tyr188 (numbered after MtPNP amino acid sequence) had been identified as the only residue that interacts directly with the bound ImmH inhibitor that is not conserved in the mammalian PNPs [85] , which shed some light on another structural feature that could be exploited to design specific inhibitors for MtPNP.
We have suggested that inhibition of MtPNP could potentially lead to the accumulation of dGTP through deoxycytidine kinase (EC 2.7.1.74) activity, which can use deoxyguanosine as substrate, synthesizing dGMP that is further converted to dGTP. For instance, dGTP inhibits the enzyme RR, restraining DNA and RNA synthesis [104, 105] . Owing to the accumulation of guanine nucleotides and of hyperphosphorylated guanosine moieties, MtPNP might, thereby, play a role in the MTB latent state in response to nutritional stress [82] . Hence, we have carried out gene replacement experiments to produce a MTB mutant strain defective in functional PNP. Surprisingly, deoD-encoded MtPNP appears to play an essential role in survival of MTB grown in rich medium, since a knockout strain could not be generated due to the unexpected essentiality of the deoD gene (unpublished results). This result underscores the need for demonstrating protein function by experimental approaches instead of assigning function to a particular gene product based only on comparative data. These data also suggest that purine salvage metabolism is probably rather more complex in MTB than previously thought. More recently, crystals diffracting at 2.15 Å were obtained for the MtPNP, sulfate, and deoxyguanosine ternary complex [91] , which should provide further insight into the mode of action of this enzyme.
Purine Nucleosidase (EC 3.2.2.1)
(other designations: NSase, purine nucleoside hydrolase, purine ribonucleosidase, and riboside hydrolase)
Encoded by the iunH gene (MTB Rv3393, 927 bp, 308 aa, 32937.50 Da, and pI = 5.15), purine nucleosidase (NSase), also known as purine nucleoside hydrolase, catalyzes the irreversible hydrolysis of all of the commonly occurring purine and pyrimidine nucleosides (N-glycosidic bond cleavage) to -D-ribose and the associated base [106] (Fig. 8) . Deoxyribonucleosides are not substrates for this enzyme, notwithstanding their source. NSases have been isolated or the respective encoding genes identified from a number of sources, including bacteria [107] [108] [109] , parasitic protozoans [110] [111] [112] [113] [114] , and yeast [115] . Since parasitic protozoans lack the de novo pathway to synthesize purine nucleosides, they rely on NSase to supply purine nucleosides by salvaging them from the host [111] . Protozoan NSases may be divided into three subclasses according to the substrate preference: the first class is devoted to the preferential usage of inosine and uridine; the second to inosine, adenosine, and guanosine; and the third to inosine and guanosine [116] . The E. coli genome also contains genes for three NSases, which have been classified based on their substrate specificity: rihA and rihB are pyrimidine-specific, whereas rihC hydrolyzes both purine and pyrimidine ribonucleosides [109] . It has been shown that the features of the transition state structure determined by kinetic isotope effects of uridine hydrolysis catalyzed by the E. coli rihCencoded enzyme are activation of the heterocyclic base by protonation of/or hydrogen bonding to O2, an extensively broken C1'-N1 glycosidic bond, decreased C1'-O4' bond distance due to oxocarbenium ion formation in the ribose ring, C3'-exo ribose ring conformation, and almost no bond formation to the attacking nucleophile [117] . The E. coli NSase proposed transition state is similar to that of Crithidia fasciculata NSase [118] .
Apparently, NSase from MTB (MtNSase) has a substrate preference for inosine and uridine. Since humans lack this enzyme, relying on a different set of enzymatic reactions to supply their nucleoside requirements, the mycobacterial enzyme appears to represent one of the most attractive target amongst the purine salvage pathway enzymes for the rational design of drugs to treat human TB, with no, or little, side effects to the human host, according to the principle of selective toxicity. We have recently PCRamplified and pET23a(+)-cloned the MTB iunH gene. The mycobacterial recombinant enzyme was expressed in its soluble form in electrocompetent E. coli C41(DE3) host cells. Homogeneous MtNSase could be obtained through a sequence of anion exchange and gel filtration chromatographic steps. Kinetic and structural studies are currently underway (unpublished data).
Inosine Monophosphate Dehydrogenase (EC 1.1.1.205)
(other designations: IMPDH, IMP dehydrogenase, inosine dehydrogenase, inosinic acid dehydrogenase, inosinate dehydrogenase, and IMP oxidoreductase)
Encoded by the guaB2 gene (MTB Rv3411c, 1590 bp, 529 aa, 54866.90 Da, and pI = 6.33), inosine monophosphate dehydrogenase (IMPDH) catalyzes the oxidation of IMP to XMP with concomitant conversion of oxidized nicotinamide adenine dinucleotide (NAD + ) to the reduced form of nicotinamide adenine dinucleotide (NADH) [119] (Fig. 9) . IMPDH has already been described in eukaryotes and prokaryotes organisms, with great degree of conservation. Formerly classified as EC 1.2.1.14, IMPDH is a key enzyme of guanine nucleotide synthesis whose activity is strictly dependent on the presence of monovalent cations [120, 121] , and classified as an IMPDH/GMPR family member. Its quaternary structure corre- sponds to a homotetramer of approximately 55 kDa per subunit, with a / barrel CORE domain that comprises the substrate binding sites, and a smaller subdomain composed by two tandem cystathione--synthase (CBS) dimer domains [122] (PDB accession codes and a thorough review on IMPDH structural features the readers will find in reference [122] ). IMPDH has received considerable interest in recent years as an important target enzyme for anticancer, antiviral, antiparasitic, and immunosuppressive chemotherapy [119, 122] . Inhibition of IMPDH causes an overall reduction in guanine nucleotide pools and, since GTP is a cofactor in the conversion of IMP to AMP, adenylate pools are also diminished. Subsequent interruption of DNA and RNA synthesis results in cytotoxicity [119] . As previously described, MTB IMPDH (MtIMPDH) is encoded by the guaB2 gene. IMPDH activity was also hypothetically attributed to the guaB1 (Rv1843c) and guaB3 genes (Rv3410c). However, only guaB2 gene has been experimentally identified by mass spectrometry proteomic assays [123] . Since it has been suggested that the IMPDH gene is present in a double copy in many species [122] , including human homologues [124, 125] , IMPDH activity for the products of MTB guaB1 and guaB3 genes cannot be discarded, even though they codify slightly shorter amino acid sequences (479 and 376 amino acids, respectively) and enzymes' activity were inferred solely by sequence homology.
Human IMPDH homologues, encoded by two separated genes, impdh1 and impdh2, and located at chromosomes 7q31.3 and 3p21.2, correspond to IMPDH type I (Genbank accession number: NC_000007.13) and type II (Genbank accession number: NC_000003.11), respectively. The two isoforms have 84% sequence identity and show similar kinetic properties [126] . It was found that type I IMPDH was prevalent in normal human leukocytes and lymphocytes, while type II predominated in tumor cells and rapidly proliferating cells [119, 124] . Both are rate limiting enzymes of guanine nucleotide synthesis and are, therefore, involved in the regulation of cell growth [124] . MtIMPDH and human IMPDH type I and II (514 amino acid residues) share amino acid sequence identity of 37.92% and 37.99%, respectively.
Structural data indicate that IMPDH enzymes undergo major conformation rearrangements upon catalysis: during initial substrate binding the enzyme adopts an open configuration, while a catalytic cysteine residue mediates a nucleophilic attack to IMP C2 atom, followed by hydride transfer to NAD + , generating NADH. When NADH departs from the active site, a mobile flap closes and docks into the vacant dinucleotide binding site. Hydrolysis of the covalent bond between cysteine and the purine ring then releases XMP [122, 127, 128] . Such conformational alterations, along with kinetic data, suggest a random substrate binding followed by an ordered product release [125, 129] . Several NAD + /NADH binding site IMPDH inhibitors take advantage of the vacant dinucleotide binding site, arresting the enzyme on a dead-end conformation, preventing XMP release [129] . One example that recently reached the market is the mycophenolic acid (MPA) prodrug mycophenolate mofetil, CellCept ® , introduced as an immunosuppressant [130] . Although showing positive results in phase I trials on the inhibition of myeloma cell proliferation [131] , MPA dose-limiting gastrointestinal toxicity limits its potential for autoimmune disorders [132] . To overcome such drawbacks, MPA quinolone derivatives were developed aiming at human type II IMPDH selectivity [130] . Since its action is based on IMPDH structural features, MPA exhibits some species selectivity as an IMPDH inhibitor. Mammalian IMPDHs are very sensitive to MPA, while microbial IMPDHs are much less so. This selectivity was explained by the conformational difference between the human and bacterial enzyme homologues in the reaction intermediate formed, in which recently formed XMP is still covalently bound to IMPDH. Depending on the position of the flap in the dinucleotide binding site, there are two conformations of such reaction intermediate; while human IMPDH seems to prefer the open conformation, according to available crystallographic data, the bacterial enzymes prefer the closed one, diminishing its susceptibility to MPA binding [119] . IMPDH inhibitors may also compete for the IMP binding site; examples of marketed drugs include ribavirin (Rebetol ® ), a broad-spectrum antiviral agent and relatively weak IMPDH inhibitor, which is now used in combination with interpheron-alpha for the treatment of hepatitis C and HIV virus infections [133, 134] . Mizoribine (Bredinin ® ) is also a IMPDH inhibitor that must be phosphorylated to its monophosphate form prior to substrate site binding, inducing a closed conformation of IMPDH [133, 134] . Ribavirin is incorporated via its triphosphate form into the viral RNA genome by the action of the viral RNA-dependent RNA polymerase. Incorporation of this non-natural nucleotide into the viral RNA forces the RNA virus into a lethal accumulation of errors. This is further amplified by the reduction of GTP pools caused by the inhibition of IMPDH by ribavirin monophosphate, since the decrease in cellular GTP pools is likely to increase the frequency of RNA incorporation of ribavirin triphosphate, a GTP analog [119] . For this same reason, MPA and nucleoside analogue inhibitors combined therapy proved to be a valid way of controlling HIV infection, targeting viral replication [135] . Experimental evidence demonstrated that MPA induces IMPDH aggregate formation concomitant with its inhibition, both in vivo and in vitro, through protein conformational change leading to perinuclear linear arrays up to 2000 kDa [134] . The same researchers also showed that when intracellular GTP pools are re-established, aggregate formation is reversed, and IMPDH activity restored; both these findings are due to GTP binding to IMPDH CBS domain, implying a possible role of intracellular energy sensor for IMPDH [134] . The CBS domain is a conserved protein domain present in the proteome of archaebacteria, prokaryotes, and eukaryotes, usually in tandem repeats [136] . Mutations in CBS domains are related to several human hereditary diseases (homocystinuria, retinitis pigmentosa, hypertrophic cardiomyopathy, and myotonia congenital), but their function and how they affect the structural and/or functional properties of enzymes they are part of are yet to be determined. CBS domains have been proposed to affect multimerization and sorting of proteins, channel gating, and ligand binding, along with intracellular metabolite sensor activity [136] . A recent report suggested that the CBS domain of IMPDH is involved in coordinating the activities of the enzymes of purine nucleotide metabolism (IMPDH, adenylo- succinate synthase and GMP reductase) and is essential for maintaining the normal ATP and GTP pool sizes in E. coli [137] . These authors also attributed a possible allosteric IMPDH activity role to CBS domains [137] .
Amino acid sequence alignments of MtIMPDH against nonredundant protein sequence data base of the National Center for Biotechnology and Information (NCBI) indicates that the mycobacterial enzyme shows the well conserved tandem CBS pair of domains. This structural conservation, along with previously described results concerning IMPDH activity and CBS domains probable cellular energetic sensor role indicate that this enzyme may play a key role in the biology of MTB. Reports that guanine nucleotide starvation induced quiescent phenotype in S. cerevisiae due to nutrient limitation [138] and of an attenuated strain of Streptococcus suis obtained after IMPDH gene knockout [139] can also indicate that the IMPDH enzyme, through its CBS domains, might act as a sensor of energetic availability and metabolic status changes, like latency entry and rescue in MTB, in addition to MTB virulence. Both structural and amino acid residue conservation features should be explored on MTB highly specific inhibitor development, since it has been shown that even 84% identity between human isoforms do not prevent IMPDH selective inhibition [140, 141] . We have recently PCR-amplified and pET23a(+)-cloned the MTB guaB2 gene. The mycobacterial recombinant enzyme was expressed in its soluble form in electrocompetent E. coli C41(DE3) host cells. Homogeneous MtIMPDH could be obtained by a purification protocol including of affinity and gel filtration chromatographic steps. Correct assignment to the structural gene encoding MtHGPRT was confirmed by measurement of the biological activity of the recombinant enzyme by steady-state kinetics (unpublished data). MtIMPDH apparent and true kinetic parameters, as well as its metal requirement and kinetic mechanism are currently underway. Cloning and characterization of protein encoded by MTB guaB1 and guaB3 genes have yet to be pursued. . Initially, the -phosphate group of GTP is transferred to the O6 of IMP, to give 6-phosphoryl IMP. Aspartate then displaces the phosphate group to form the product, adenylosuccinate (Fig. 10) [142] .
This three-substrate enzyme is present in a broad range of organisms and cell types, with exception of mature erythrocytes [143] . Mammalian cells present two isoforms of the enzyme, the basic and acidic isozymes [144] , whereas bacteria possess a single form. The regulation of this enzyme, which is involved in maintenance of ATP/GTP ratios in the cell, can be effected by the products of its catalyzed reaction (GDP and adenylosuccinate) and by the end products of the pathway (AMP and GMP) [145] . According to its protein sequence, MTB ADSS (MtADSS) is expected to be highly similar to many bacterial homologues. The enzyme from E. coli, and perhaps from other sources, undergoes significant conformational changes upon IMP binding, which organizes the catalytic machinery of the active site [143, 146] . Indeed, IMP binding may play an important physiological role in the regulation of ADSS activity by stabilizing the assembly of inactive monomers into active dimers [147] . Based on the consensus oligomeric state of homologues from other sources, where it is essential [142, 143, 148] , the enzyme from MtADSS is very likely to be active as a homodimer. Some inhibitors have been considered for ADSS; one of the most studied, hadacidin, a competitive inhibitor with respect to aspartate, coordinates the active site Mg 2+ with its N-formyl group and packs against the base moiety of IMP [149] [150] [151] [152] . We have recently PCR-amplified and pET23a(+)-cloned the MTB purA gene. The mycobacterial recombinant enzyme was expressed in its insoluble form in electrocompetent E. coli BL21(DE3). Efforts to improve protein solubility or to express ADSS in the soluble form are currently underway (unpublished data).
Adenylosuccinate Lyase (EC 4.3.2.2)
(other designations: ADSL, adenylosuccinase, and succino AMPlyase)
Encoded by the purB gene (MTB Rv0777, 1419 bp, 473 aa, 51008.30 Da, and pI = 6.33), adenylosuccinate lyase (ADSL) catalyses two steps in the purine pathway: the conversion of succinylaminoimidazolecarboxiamide ribonucleotide (SAICAR) into aminoimidazolecarboxiamide ribonucleotide (AICAR) in the de novo pathway; and the conversion of adenylosuccinate (also named succinyladenosine monophosphate) into AMP and fumarate throughelimination in the purine salvage pathway (Fig. 11) [153] . ADLS belongs to the fumarase superfamily of enzymes, which catalyze reactions with fumarate as one of the products, with high conservation of protein's tertiary structure without corresponding primary structure conservation [154, 155] . Structural dissimilarities between SAICAR and adenylosuccinate indicated which groups make no specific contact to the enzyme's active site, since no major ADSL rearrangements occur due to binding of both substrates [153, 156] . Further evidence that no enzyme structural modification is necessary for both substrate binding arose from P. falciparum ADSL studies, in which it was demonstrated that the homogeneous form of the enzyme was capable of catalyzing the ADSL de novo reaction in vitro, even though such pathway is absent in this parasite [153] . Fig. (10) . Adenylosuccinate synthase catalyzes the first committed step in the conversion of IMP to AMP. IMP and L-aspartate are conjugated in a two-step reaction accompanied by the hydrolysis of GTP to GDP. Initially, the -phosphate group of GTP is transferred to IMP. Aspartate then displaces the phosphate group to form the product, adenylosuccinate.
MTB ADSL (MtADSL) primary structure pairwise alignment to human and Bacillus subtilis (one of the best characterized ADSL enzymes) homologues indicate 29.13% and 23.95% identity, respectively. B. subtilis ADSL (GenBank accession code NC_000964.3) is a homotetramer comprised by 431 amino acids per subunit, also coded by a purB gene [157, 158] . Human ADSL, encoded by the adsl gene (also denoted as amps) and located at chromosome 22q13.1-13.2 (GenBank accession code NC_000022.10) has each subunit composed by 484 amino acids with 54,889 Da. Crystallographic structures have already been solved for the human homologue bound to AMP (PDB accession code 2J91) and to adenylosuccinate, fumarate, and AMP (PDB accession code 2VD6). Defects in ADSL are the cause of adenylosuccinate deficiency characterized by the accumulation in the body fluids of succinylaminoimidazolecarboxamide riboside and succinyladenosine, associated with autism, psychomotor retardation, and, in some cases, growth retardation associated with muscle wasting and epilepsy [153] . Several point mutations, such as P75A, D397Y, R401H, and S413P, are associated with defective enzyme [157] and are located outside the ADSL active site, most probably rendering structurally unstable enzymes [158] . Besides not being attributed to a single cause, severity of adenylosuccinate deficiency clinical phenotype correlates with ADSL activity level [159, 160] .
Together, the reactions catalyzed by ADSS and ADSL form the purine nucleotide cycle [155] , and regulate cellular metabolism by controlling fumarate, a citric acid cycle intermediate, and free AMP levels [156] . ADSL enzymes are homotetramers with approximately 52 kDa per subunit, where three subunits contribute with amino acids to the active site located on such interface [161] , with histidine residues from two distinct subunits taking part on catalysis [153, 157] . The -elimination of fumarate on both ADSL catalyzed reactions proceed through a general base-general acid mechanism, in which His68 and His141 in B. subtilis and Thermotoga maritima are involved [156, 157, 162] . The enzyme mechanism is uni-bi mechanism with either steady-state [163, 164] or rapid equilibrium [153] ordered product release, where fumarate departs first from the ADSL active site. Site-directed mutagenesis experiments and crystallographic data of E. coli ADSL indicate, however, that His141, and not His68, is the general acid, and a serine residue, located in a mobile loop that closes the ADSL catalytic site upon substrate binding, is the general base [165] . All these residues are conserved in the MtADSL homologue, corresponding to His76, His147, and Ser277, and are also observed among all ADSL homologues described [156] . A third fully conserved histidine residue, corresponding to MtADSL His95, was implicated in substrate binding and proper orientation for catalysis by sitedirected mutagenesis and crystallographic data analysis [158] .
Metabolic adaptations to environmental energetic status are related to the shift between the de novo and salvage pathways of purine synthesis. It has already been shown that pathogenic mycobacteria are able to change purine salvage enzyme expression, owing to purine base supplementation [166] . Further experiments in E. coli demonstrated that all genes involved in IMP synthesis are repressed upon hypoxanthine supplementation, and that such gene expression, along with genes of GMP synthesis, are regulated by a common PurR repressor, encoded by the purR gene. The PurR repressor is know to bind PUR box-like sequences (gaaaacgtttnc) found in the promoter region of purine related genes, as well as downstream from transcriptional start region of the purR own gene [167] . E. coli purB gene differs in its regulation patterns by upregulating under limiting adenine conditions, even with hypoxanthine or guanine excess [168] , indicating that the purB gene is regulated by the purine pool and purR [169] . No homologue to purR gene has been observed in the MTB genome, nor were PUR box-like sequences identified in the purB gene, indicating that MtADSL might be responsive only to purine pools, which corroborates the free AMP level regulation activity attributed to the purine nucleotide cycle [155] . Aside from a role in energetic sensing, ADSL from B. subtilis has been shown to act as a regulatory factor of glutamil-tRNA synthetase, an enzyme involved in protein biosynthesis, which is a high energy demanding process [170] . ADSL may, thus, couple purine and protein biosynthesis, regulating AMP biosynthesis and maintaining cellular ATP/AMP ratio [171] .
ADSL crystallographic data could not provide unequivocal evidence of amino acid residues involved in substrate binding specificity, especially for being a single substrate enzyme, thus requiring enzyme co-crystallization with possible inhibitors to allow active site inspection [172] ; however, ADSL homologues have broadsubstrate specificity [173] , which limit the information that can be extracted from structural data to further develop specific inhibitors. A non-cleavable substrate analog, adenosine phosphonobutyric acid, 2'(3'), 5'-diphosphate (APBADP), was shown to be a competitive inhibitor of B. subtilis ADSL with K i values of 0.18 ± 0.04 M and 0.16 ± 0.04 M when tested against adenylosuccinate and SAICAR substrates, respectively. For human ADSL, these values were 0.09 ± 0.04 M and 0.21 ± 0.08 M, respectively [174] . AP-BADP structure presents two extra phosphate groups, in the ribose ring and in the four-carbon chain [174] ; these additional groups impair ADSL to properly arrange the molecule for catalysis [153] . Structural comparison between both ADSL natural substrates to identify conserved chemical groups, knowledge of potential amino acid residues involved in catalysis, and stereochemical restrains might be exploited for ADSL specific inhibitors development. We have recently PCR-amplified, pET23a(+)-cloned the MTB purB gene. The mycobacterial recombinant enzyme was expressed in its soluble form in electrocompetent E. coli BL21(DE3) host cells. Availability of homogeneous MtADSL, currently underway, will enable to assign ADSL activity to this mycobacterial enzyme (unpublished data).
Nucleoside Monophosphate Kinases
Nucleotide triphosphates (NTP) are DNA and RNA precursors and critical regulators in diverse cellular pathways. An essential Fig. (11) . In the purine salvage pathway, adenylosuccinate lyase catalyses the conversion of adenylosuccinate into AMP and fumarate through a -elimination.
step for their synthesis relies on the conversion of nucleoside monophosphates (NMP) to nucleoside diphosphates (NDP), a process that involves the reversible transfer of the -phosphoryl group of ATP to an NMP acceptor by NMP kinases. Two purine NMP kinases are responsible for these activities in MTB: guanylate kinase and adenylate kinase. Based on the structures solved to date (PDB accession codes and a in-depth review on NMP structural features the readers will find in reference [175] ), all purine NMP kinases consist of a CORE domain with the LID domain and the NMP-binding domain attached to it [175] . Even though prokaryotic NMP kinases share a similar modular architecture with their eukaryotic counterparts, in many cases they display singular features that are solely observed in bacteria or bacterial groups. Since unique enzymological properties can be studied to explore potential antibacterial targets, this group of enzymes might also be worth the effort. Encoded by the gmk gene (MTB Rv1389, 627 bp, 208 aa, 22063.10 Da, and pI = 7.58), guanylate kinase, also known as guanosine monophosphate kinase (GMK), is an essential enzyme that recycles GMP (and, indirectly, cGMP) by catalyzing the reversible transfer of a phosphate group from ATP to GMP, yielding ADP and GDP (Fig. 12) . dGMP can also act as an acceptor, and dATP can act as a donor; Mg 2+ is a critical component of catalysis, whose binding to GMK is enhanced by the presence of both substrates [176] . This enzyme plays an essential role in the biosynthesis of GTP. It also has a medicinal importance as it activates guanosine analog prodrugs, like some antiviral and anticancer agents, such as mercaptopurine, thioguanine, acyclovir, ganciclovir, and carbovir, among others [177] [178] [179] .
As is evident from the structure (PDB accession code 1LVG), mouse GMK has a clamp-like cavity, where the two lobes of the protein close through an approximately 1 nm conformational change upon binding the substrates [180] ; most of this conformational motion is induced by the binding of GMP. The substrates drive this conformational change through several direct and indirect (via water molecules) interactions that bring the LID and NMPbinding domain together and towards the CORE region, the structure closing in a vise-like motion [180, 181] . In this configuration, the CORE is catalytically active towards phosphoryl transfer, which relies on a residue sequence (the P-loop) that is conserved in kinases [182] . Using a nanotechnology approach based on controlled mechanical stress to bias conformational states in favor of GMK open (without substrates) conformation, it could be observed that the binding affinity for GMP is considerably reduced, whereas ATP binding constant and the catalytic rate remain essentially unaffected. Since the binding of GMP does not control, allosterically or cooperatively, the binding of ATP to the enzyme, it must allosterically control catalysis itself or, at least, the ATP hydrolysis step. The concept of using mechanical stress to control the conformation of a protein can be applied to virtually any protein to study the fundamental mechanisms of allostery from a new perspective [183] .
Based on the crystal structure, MTB GMK (MtGMK) is a monomeric enzyme that displays a low catalytic efficiency (as previously mentioned) in relation to eukaryotic homologues, an unusual specificity for ATP as a phosphate donor, and carries two redox-sensitive cysteines in the central CORE domain. Although MtGMK has a modular domain structure as most NMP kinases, the unusual CORE domain conformation and the partially open LID and GMP-binding domains (which are the same in the apo, GMPbound, and GDP-bound forms) relative to the CORE of the mycobacterial enzyme point to considerable differences to the eukaryotic homologues [184] , which could be explored towards development of drugs with selective activity. We have PCR-amplified and pET23a(+)-cloned the MTB gmk gene. Efforts to produce the recombinant protein in electrocompetent E. coli commercial variants available for heterologous expression is currently underway (unpublished data). -dependent high-energy phosphoryl transfer from ATP to AMP, releasing two ADP molecules, thereby regulating the adenine nucleotide composition within the cell [185] ; it also accepts dAMP (Fig. 13) . This small ubiquitous enzyme is essential in intracellular nucleotide metabolism, and has been found to act as both a NMP and NDP kinase, suggesting that it may have a role in RNA and DNA biosynthesis [186] .
The ADK family has been classified into two groups based on the polypeptide chain length, in which the long variants present a longer LID domain [187] . Several isoforms have been identified in eukaryotes, with diverse size and cell, tissue, and organ distribution [188, 189] . Eukaryotic cytosolic enzymes belong to a short type of ADK, while the bacterial, yeast, and mitochondrial enzymes generally belong to the long type. In the enzyme from MTB (MtADK), a representative of a new proposed subfamily of short bacterial ADK variants [187] , the LID is reduced to a small irregular loop; the rest of the primary structure, overall fold, and side chains that are involved in catalysis and nucleotide binding are, however, conserved in all variants [190, 191] . This monomeric enzyme, which is essential for bacterial survival, displays an unexpectedly high thermal stability [187] and a compact and rigid structure [187, 192] , possibly due to the considerably short LID domain, and a noticeably low catalytic activity, which could be related to its singular structural and dynamic features [193] or to a functional role in its slow growing phenotype or even latent state survival process [187] . MtADK crystal structure in complex with two ADP molecules and Mg 2+ (PDB accession code 2CDN) revealed significant conformational changes of the LID and NMP-binding domain upon substrate binding. The ternary complex represents the state of the enzyme at the start of ATP synthesis reaction, and is consistent with the direct nucleophilic attack of a terminal oxygen from the acceptor ADP molecule on the -phosphate from the donor substrate, and hints to Fig. (12) . Guanylate kinase catalyzes the reversible transfer of a phosphate from ATP to GMP, yielding ADP and GDP.
an associative mechanism for phosphoryl transfer [192] . MtADK seems to display structural and catalytic features considerably different from the ones observed in the eukaryotic and prokaryotic homologues [187, 194] , an essential fact for selective drug target design with little or no effect on eukaryotic isoforms. , yielding GMP, PP i , AMP, and L-glutamate [195] ; the enzyme also accepts dXMP (Fig. 14) . The irreversible transfer of an amino group from glutamine to the C2 atom of XMP via an adenyl-XMP intermediate characterizes the G-type family of glutamine amidotransferases (GAT) that utilize glutamine as the main ammonia source [196] . Guanine nucleotide products are not only essential for DNA and RNA synthesis, but also provide GTP for a number of essential cellular processes [197] . Both prokaryotic and eukaryotic GMPS homologues show a tertiary structure composed by two distinct domains, a GAT domain at its N-terminal portion, where glutamine is hydrolised to glutamate and ammonia, and an ATP pyrophosphatase (ATPPase) C-terminal domain, where the adenyl-XMP intermediate is formed [196] . Ammonia is channeled between these two domains in a substrate-protective environment, ensuring an efficient catalysis. The presence of two separate although connected domains, further classifies GMPS as a Class I amidotransferase [198, 197] . Even though it has already been shown that the glutaminase activity might be independent from XMP or ATP binding to ATPPase domain, GMPS only achieves maximum activity upon binding of both substrates to the C-terminal domain [196] , highlighting both active sites concerted action [198, 197] .
The human counterpart corresponds to a 693 amino acid protein, codified by the umps gene, located at the chromosome 3q24 (GenBank accession code NM_003875); even being considered a particularly interesting target for anticancer and immunosupprecive therapies [199] , literature relating to human and other GMPS homologues are considerably scarse. Unlike P. falciparum, that presents a homodimeric quaternary structure, human GMPS seems to be a monomer in solution [196] .
Despite differences on quaternary organization, all GMPS noted to date exhibit a conserved cysteine residue on their GAT domain, involved in the hydrolysis of glutamine, which corresponds to Cys93 in MTB GMPS (MtGMPS) [199, 200] . Acivicin has been identified as a selective inhibitor of human GMPS glutaminase activity, abolishing GAT function while preserving ATPPase mediated XMP amination in the presence of Mg 2+ , ATP, and XMP, indicating that these ligands might be necessary for the cysteine residue to become a reactive nucleophile. Thereby, acivicin totally inhibit GMPS activity when glutamine is the sole ammonia source, by forming an imino-thioesther linkage to the conserved active site cysteine residue [199, 201] . Notwithstanding such catalytic residue absolute conservation, and perhaps a conserved catalytic mechanism, a comparative analysis of GMPS conding genes across prokaryotes and eukaryotes indicated mammalian orthologs as a clearly diverged branch [202] , a positive indicative that high specific inhibitors towards pathogens may be identified.
MtGMPS might be an interesting target for drug development due to its role in GMP synthesis. It is important to point that disruption of the guaA gene from Francisella tularensis, the causative agent of tularemia, has already been shown to result in attenuated strain guanine auxotrophs, unable to replicate within macrophages, presenting decreased numbers over infection time [203] ; the corresponding gene is also essential for survival and infectivity of Borrelia burgdorferi, the infectious agent of Lyme borreliosis [204] . We have recently PCR-amplified and pET23a(+)-cloned the MTB guaA gene. The mycobacterial recombinant enzyme was expressed in its soluble form in electrocompetent E. coli BL21(DE3) host cells. Homogeneous dimeric MtGMPS could be obtained through a sequence of anion exchange, gel filtration, and hydrophobic interaction chromatographic steps. Kinetic and structural studies are currently underway (unpublished data). Fig. (14) . Guanosine monophosphate synthase catalyses the irreversible conversion of XMP into GMP though a reaction that requires ATP and involves the transfer of an amino group from L-glutamine to the C2 of XMP via an adenyl-XMP intermediate.
SUMMARY
The current situation imposed by human TB demands urgent development of new and more effectivet drugs to combat mycobacterial drug-resistance and, hopefully, latency. Enzymes from the purine salvage pathway seem to be attractive molecular targets on which to base the development of inhibitors to be used against this infectious disease, since purine analogues were already found to be toxic for bacterial cell growth. Although some of these enzyme activities are shared between MTB and the human host, it is possible to develop inhibitors with selective activity against the pathogen's enzymes by exploiting differences in their functional and structural features. 
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